#ASCO23 ASCO Fantastic discussion of LIBELULE - a study of early integration of Liq Bx in #NSCLC Joel W. Neal, MD, PhD - reduced Time to Tx start - ctDNA tumor fraction may be helpful OncoAlert LungCancerRx 🫁💊

1/10 I left #ASCO23 last week feeling INSPIRED about the pace of progress & discovery for cancer patients! I'm excited about2⃣ precision oncology themes from the meeting, and it seems others in the oncology community share my excitement: bit.ly/3N8XpBg

8/10 I’m also AMAZED🤯by the #ASCO23 LIBELULE study, a randomized trial demonstrating that early liquid biopsy for radiologic suspicion of stage IV lung cancer reduces time to initiation of 1st-line therapy: bit.ly/3qIS4cE

d.planchard Gustave Roussy Centre International des Cancers Thoraciques En effet, dans beaucoup d’établissements AP-HP Hôpital Tenon AP-HP. Mais nous savons aussi que les contraintes des essais font que 5, 10, 30% des malades seront incluables; c’est l’objet pour les autres des accès précoces pour des molécules d’intérêts Julien Mazieres Maurice Perol denis Moro-Sibilot

cadranel jacques Julien Mazieres denis Moro-Sibilot Marie Wislez Gerard ZALCMAN Rémi Veillon Vincent Fallet Benjamin Besse Laurent Greillier Michael Duruisseaux Maurice Perol Sébastien Couraud 🫁🚭🌍 Dr Clarisse Audigier-Valette🫁🩻🏥

I love the work of the NADIM group. 🇪🇸 But someone has to point out the publication bias of the NEJM front office. This is a phase II with 86 patients and a median f/u of only 26 months. These studies are generally rejected by NEJM reviewers. nejm.org/doi/full/10.10…

Vivek Subbiah, MD denis Moro-Sibilot Haute Autorité de santé cela pourrait il être suffisant pour débloquer la situation en France? Mon Réseau Cancer du Poumon alk ros1 france cancer poumon Julien Mazieres Benjamin Besse Maurice Perol Marie Wislez Michael Duruisseaux IFCT lung Laurent Greillier

senat.fr/rap/r22-828-1/…

The ESMO Handbook on Nutrition and Cancer (Second edition) is out now. Excellent publication and free for ESMO - Eur. Oncology Members. Please download oncologypro.esmo.org/education-libr… OncoAlert BTOG Christie Library

Stephen V Liu, MD It is a very important news for French pts with RET fusion advanced NSCLC as France did not accept selpercatib nor praseltinib access even conditional Haute Autorité de santé Ministère de la Santé et de la Prévention Aurélien Rousseau it is time to have to selpercatinib access. alk ros1 france cancer poumon Mon Réseau Cancer du Poumon IFCT lung

Pilar Garrido Lizza Hendriks d.planchard Anne-Marie Dingemans Enriqueta Felip ESMO - Eur. Oncology Beaumont RCSI Cancer Centre - charocampelo: neoadj + adj IO - me! Jarushka Naidoo: mesothelioma, thymoma Lisbon in November, will be fun ESMO - Eur. Oncology #LCSM #IrishLungCancerAlliance #IrishLungCancerCommunity RCSI Research and Innovation

Michael Duruisseaux And access to selpercatinib for the French RET+ NSCLC patients for whom there is no drug available in early access. @HAS refused this access in absence of CT comparative trials by contrast to other UE countries. It is time to urgently change this inequality Ministère de la Santé et de la Prévention

We publish an update on the multidisciplinary management of TKI-induced diarrhea, a problem that affects the patient's quality of life, even in grade 1 due to long-term treatment Instituto Nacional de Cancerología UFOT INCan Jenny Turcott Andres F. Cardona journals.sagepub.com/doi/epub/10.11…

Un milliard de morts ☠️ sur la planète depuis l’invention de la cigarette. C’est sûr que vous pouvez être “fiers” du chemin parcouru ! 😡

Press release: two phase III studies of lenvatinib + pembrolizumab in NSCLC negative. LEAP-006 was 1L platinum + pemetrexed + pembrolizumab +/- lenvatinib did not improve OS. LEAP-008 was 2L pembro + lenvatinib vs docetaxel (post-IO). Await full data. merck.com/news/merck-and…

#ESMO23 Poster 1373P with outcomes from TRUST-II of talectrectinib in #ROS1 NSCLC. 1L RR 92% with 80% intracranial response rate, medians not reached. Dizziness does not seem to be a major issue with this agent, perhaps TrkB selection important?

🎯ROS1. Impressive results with taletrectinib. 92% RR (👍👍) and 57% following previous ROS1 tki (👍). #ESMO23 OncoAlert Maurice Perol

Fantastic presentation by Zosia Piotrowska - balanced, thoughtful and poised discussion of MARIPOSA and MARIPOSA-2 ESMO Open #ESMO23 ➡️ Highlights that chronic toxicities, even low grade can affect QOL, cc Jill Feldman ➡️ Patient oriented approach will be KEY! EGFR Resisters

Thank you for the invitation IASLC ! Promising results for #BRAF-mutant lung cancer, yet much to be done re. - Therapy sequence (ICI vs targeted therapy) - Resistance to therapy We work on some of these challenges in the #BOLEROConsortium #LCAM23 #LCSM CRCL Centre Leon Berard

C’est maintenant l’heure de la « lecture critique d’articles » : merci à Florian Guisier et Aurélie Swalduz! #17eme_Réunion_Clinico_Pathologique_en_Oncologie_Thoracique GFPC